Shire PLC (SHP.L)

SHP.L on London Stock Exchange

4,468.00GBp
25 Nov 2014
Price Change (% chg)

-27.00p (-0.60%)
Prev Close
4,495.00p
Open
4,497.00p
Day's High
4,549.00p
Day's Low
4,454.00p
Volume
1,494,824
Avg. Vol
3,152,305
52-wk High
5,470.00p
52-wk Low
2,620.00p

SHP.L

Chart for SHP.L

About

Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in... (more)

Overall

Beta: 0.62
Market Cap (Mil.): £26,413.13
Shares Outstanding (Mil.): 589.57
Dividend: 2.24
Yield (%): --

Financials

  SHP.L Industry Sector
P/E (TTM): 22.06 38.28 39.18
EPS (TTM): 2.03 -- --
ROI: 26.16 17.89 17.24
ROE: 37.75 18.63 18.11
Search Stocks

Drugs company Shire relocates 500 jobs to Massachusetts

LONDON, Nov 19 - Drugs company Shire said on Wednesday it would move over 500 jobs from its Chesterbrook, Pennsylvania site to Lexington, Massachusetts, to save costs by combining its worldwide R&D and commercial operations in two locations.

19 Nov 2014

Scuttled deals worth $580 bln put hedge funds on back foot

* Event driven funds lose $3.3 bln in outflows in two months

13 Nov 2014

Elliott Associates may sue AbbVie over scuttled deal

BOSTON - Hedge fund Elliott Associates may take legal action against pharmaceuticals company AbbVie Inc for scuttling a merger deal with Shire Plc.

05 Nov 2014

UPDATE 1-Elliott Associates may sue AbbVie over scuttled deal

BOSTON, Nov 5 - Hedge fund Elliott Associates may take legal action against pharmaceuticals company AbbVie Inc for scuttling a merger deal with Shire Plc.

05 Nov 2014

AbbVie says strong results lessen need for big deal

- AbbVie, which this month abandoned its planned $55 billion purchase of Dublin drugmaker Shire , reported impressive quarterly earnings on demand for its Humira arthritis drug and said it could deliver strong long-term growth without rushing into another big merger attempt.

31 Oct 2014

UPDATE 2-AbbVie says strong results lessen need for big deal

Oct 31 - AbbVie, which this month abandoned its planned $55 billion purchase of Dublin drugmaker Shire, reported impressive quarterly earnings on demand for its Humira arthritis drug and said it could deliver strong long-term growth without rushing into another big merger attempt.

31 Oct 2014

U.S. law firm says investigating AbbVie over collapsed Shire deal

LONDON - U.S. law firm Gardy & Notis, a shareholder rights advocate, said on Wednesday it was investigating AbbVie and its officers over statements made in connection with the drugmaker's failed move to buy Dublin-based Shire .

29 Oct 2014

U.S. law firm says investigating AbbVie over collapsed Shire deal

LONDON, Oct 29 - U.S. law firm Gardy & Notis, a shareholder rights advocate, said on Wednesday it was investigating AbbVie and its officers over statements made in connection with the drugmaker's failed move to buy Dublin-based Shire.

29 Oct 2014

Britain's FTSE falls, posts strongest week since August

* Shire gains strongly after mid-session results (Updates with closing prices)

24 Oct 2014

Britain's FTSE falls, still set for strongest week since August

* Shire gains strongly after mid-session results (Adds quote, detail,m updates prices)

24 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks